Glaxosmithkline

18561 Words75 Pages
GlaxoSmithKline company profile

Francis Weyzig

Amsterdam, October 2004

Summary
Business description
GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. Headquarters: UK, with additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figures for 2003 (in £ million) Sales 21,441 Materials and production costs 4,188 Marketing and administration 7,563 R&D expenditures 2,770 Operating income 6,920 Net profit 4,765 GSK has two main business divisions, pharmaceuticals and consumer
…show more content…
The pharmaceutical industry is represented in the GAVI Board. The GAVI has identified three priority diseases: Hepatitis B, Haemophilus influenza type b and yellow fever. This focus has been criticized. GSK is a major supplier of Hepatitis B vaccines to GAVI, with supplies worth over $200 million for the period 2001-2004. The GAELF is GSK’s flagship community programme. It was founded in 1998, aiming to eliminate lymphatic filariasis by 2020. GSK has committed to provide as much of its drug albendazole as required until the disease is eliminated. The drug is administered through national programmes in 34 countries. GSK also contributed cash grants and expertise. The total quantity of required albendazole for 20 years is estimated at 6 billion tablets, with a value of some $1 billion (at wholesale prices). The AMP was established in 2002 to reduce malaria infections and improve the

management of the illness. The partnership targets seven African countries. National ministries of health and international NGOs are directly involved. GSK provided a £1.5 million grant to fund country programmes for three years. During this period, the company seeks to demonstrate the success of the partnership and attract other donors. In 2003 the total value of GSK’s product, cash and in-kind donations was £338 million.

Analysis of GPPI involvement
Although the global community partnerships of GSK have a philanthropic nature, they also serve to build pride with employees. These GPPIs
Get Access